Yulia Slavina

Arcturus Therapeutics unveils dietary and biochemical data from ARCT-810 study

Arcturus Therapeutics unveils dietary and biochemical data from ARCT-810 study
Arcturus showcases ARCT-810 study

Arcturus Therapeutics presented new research on its ARCT-810 mRNA therapy for ornithine transcarbamylase (OTC) deficiency at the SSIEM 2026 conference. The presentation, delivered by Tope Pedro, featured findings on the impact of the therapy on dietary intake and biochemical data in adolescent and adult patients.

This research offers fresh insights into the potential of ARCT-810 as a treatment option for individuals with OTC deficiency, reflecting ongoing advancements in gene-based therapies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.